- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations Investing
- Private Equity
- Real Estate
- Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Franchise and Hospitality
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Coronavirus
- Crisis Practice
- Environmental Agenda
- Focus on Women's Health
- Special Purpose Acquisition Companies (SPACs)
- The New Administration: Enforcement and Legislative Impact
- Careers
- News & Insights
- About
- Languages
D. Kyle Sampson
News 6 results
In the News · Source: Medtech Insight
In the News · Source: Bloomberg Law
In the News · Source: MedTech Insight
November 16, 2020
Kyle Sampson explains why the new U.S. Congress will work quickly to reestablish key provisions of the Affordable Care Act
In the News · Source: Medtech Insight
September 22, 2020
Kyle Sampson discusses how the U.S. Supreme Court shake-up will impact the medical device industry
Events 9 results
Webinar
September 9, 2021
14th Annual King & Spalding Medical Device Summit
Speaking Engagement
March 23, 2021
Kyle Sampson to Speak on 8th Annual Legal, Regulatory, and Compliance Forum on Cosmetics & Personal Care Products Virtual Conference
Webinar
February 23, 2021
FDA Inspections in 2021 for Drug and Device Manufacturers
Webinar
November 10, 2020
13th Annual King & Spalding Medical Device Summit
Insights 28 results
Client Alert
August 27, 2021
FDA Rejects Bids To Market CBD-Based Dietary Supplements
Client Alert
August 6, 2021
FDA Finalizes “Intended Use” Regulations
Client Alert
May 5, 2021
Genus Medical Technologies LLC v. FDA: D.C. Circuit Holds FDA Cannot Regulate Devices as Drugs